Scibase AB (SCIB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scibase AB (SCIB) has a cash flow conversion efficiency ratio of -3.129x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-20.82 Million ≈ $-2.24 Million USD) by net assets (Skr6.66 Million ≈ $716.29K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SCIB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Scibase AB - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Scibase AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Scibase AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scibase AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Petpal Pet Nutrition Technology Co Ltd
SHE:300673
|
0.013x |
|
Banco de Valores SA
BA:VALO
|
1.856x |
|
Orange County Bancorp Inc
NASDAQ:OBT
|
0.106x |
|
Hwail Pharmaceutical Co.Ltd
KQ:061250
|
0.033x |
|
GULF KEYSTONE PETR.
F:GVP1
|
N/A |
|
Hua Eng Wire & Cable Co Ltd
TW:1608
|
0.026x |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
-0.412x |
|
Everbright Jiabao Co Ltd
SHG:600622
|
0.042x |
Annual Cash Flow Conversion Efficiency for Scibase AB (2012–2025)
The table below shows the annual cash flow conversion efficiency of Scibase AB from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Scibase AB market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr6.66 Million ≈ $716.29K |
Skr-84.58 Million ≈ $-9.10 Million |
-12.707x | -711.59% |
| 2024-12-31 | Skr36.65 Million ≈ $3.94 Million |
Skr-57.38 Million ≈ $-6.18 Million |
-1.566x | -29.68% |
| 2023-12-31 | Skr43.06 Million ≈ $4.63 Million |
Skr-51.98 Million ≈ $-5.59 Million |
-1.207x | +31.48% |
| 2022-12-31 | Skr25.24 Million ≈ $2.72 Million |
Skr-44.47 Million ≈ $-4.79 Million |
-1.762x | -215.78% |
| 2021-12-31 | Skr70.80 Million ≈ $7.62 Million |
Skr-39.50 Million ≈ $-4.25 Million |
-0.558x | +22.78% |
| 2020-12-31 | Skr46.86 Million ≈ $5.04 Million |
Skr-33.86 Million ≈ $-3.64 Million |
-0.723x | +39.05% |
| 2019-12-31 | Skr32.01 Million ≈ $3.45 Million |
Skr-37.96 Million ≈ $-4.08 Million |
-1.186x | -126.10% |
| 2018-12-31 | Skr71.48 Million ≈ $7.69 Million |
Skr-37.48 Million ≈ $-4.03 Million |
-0.524x | -37.36% |
| 2017-12-31 | Skr115.72 Million ≈ $12.45 Million |
Skr-44.18 Million ≈ $-4.75 Million |
-0.382x | -47.93% |
| 2016-12-31 | Skr185.41 Million ≈ $19.95 Million |
Skr-47.85 Million ≈ $-5.15 Million |
-0.258x | -61.43% |
| 2015-12-31 | Skr291.42 Million ≈ $31.36 Million |
Skr-46.59 Million ≈ $-5.01 Million |
-0.160x | +85.92% |
| 2014-12-31 | Skr32.65 Million ≈ $3.51 Million |
Skr-37.08 Million ≈ $-3.99 Million |
-1.136x | -20.76% |
| 2013-12-31 | Skr36.18 Million ≈ $3.89 Million |
Skr-34.03 Million ≈ $-3.66 Million |
-0.940x | -161.14% |
| 2012-12-31 | Skr-23.69 Million ≈ $-2.55 Million |
Skr-36.44 Million ≈ $-3.92 Million |
1.538x | -- |
About Scibase AB
SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin c… Read more